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Background: Asymmetric Dimethylarginine (ADMA) is an inhibitor of endogenous nitric oxide synthase, which is
the key synthase for nitric oxide (NO) production. Whether statins could protect endothelium by reducing ADMA
concentration is unclear, and whether this effect is associated with the dose of statins usage is also needed further
studied.
Methods: Dyslipidemia rat model was produced by giving high-fat and high-cholesterol diet for 8 weeks. Thereafter,
low-dose (5 mg/kg body weight/day) and high-dose (20 mg/kg body weight/day) atorvastatin were orally prescribed
for 4 weeks. Parameters of interest including lipid profiles, inflammatory and oxidative markers, NO production and
plasma levels of ADMA and ADMA concentration of myocardium were evaluated. Liver enzymes and creatinine kinase
(CK) were also detected for safety concern.
Results: At baseline, all parameters were comparable between the sham and the dyslipidemia groups. At 8 weeks of
dyslipidemia establishment, as compared to the sham group, body weight and lipid profiles were significantly elevated,
and plasma levels of C-reactive protein (CRP), malondialdehyde (MDA) and ADMA were concomitantly increased in
accompanying with NO reduction in the dyslipidemia groups. With 4 weeks of atorvastatin therapy, as compared to
the control group, lipid disorders and NO production were improved, and plasma levels of CRP, MDA and ADMA were
significantly decreased in the high-dose atorvastatin group. ADMA concentration of cardiac tissues was also significantly
reduced in the high-dose atorvastatin group. Notably, there was a trend to similar effects which did not reach statistical
significance in the low-dose atorvastatin group when compared to the control group. Liver enzyme and CK were
comparable after 4 weeks of atorvastatin therapy between groups.
Conclusion: In rats with dyslipidemia, atorvastatin therapy could reduce plasma level of ADMA and ADMA
concentration in cardiac tissues, and these effects are associated with the dose of atorvastatin therapy.
Keywords: Dyslipidemia, Endothelium function, StatinsIntroduction
Atherosclerotic cardiovascular disease (ASCVD) mainly
including coronary artery disease and ischemic stroke is
still the leading cause of morbidity and mortality world-
wide despite great improvement has been achieved in
the past decade [1]. As is well known that endothelial
dysfunction is implicated in the development and pro-
gression of atherosclerosis and ASCVD [2,3], and previ-
ous many studies have shown that increased nitric oxide* Correspondence: ldj168168@yeah.net; wymai@hotmail.com
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unless otherwise stated.(NO) production by statins therapy contributed to better
outcomes in experimental and clinical studies [4-6].
Asymmetric dimethylarginine (ADMA), a specific in-
hibitor of endogenous nitric oxide synthase (eNOS), is
capable of decreasing NO production and may also
accelerate atherosclerosis progression as suggested by
previous studies [7-9]. For example, Sahinarslan A and
colleagues reported that in subjects with stable angina,
plasma ADMA concentration was positively correlated
with coronary atherosclerotic score [10]. Moreover, in-
creased plasma ADMA concentration might be a good
indicator for predicting the severity of coronary arteryThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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the setting of dyslipidemia, ADMA concentration was
promoted which consequently leaded to endothelial
dysfunction [11]. Outcome from subsequent clinical
observational studies further supported the notion that
ADMA might be a novel therapeutic target for prevent-
ing and treating atherosclerosis and ASCVD [7-9].
Knowingly, dyslipidemia is the major risk factor for
atherosclerosis and ASCVD worldwide [12], and statins
improved outcomes of ASCVD largely through modify-
ing dyslipidemia as well as improving endothelial
function [13,14]. However, in the early stage of dyslip-
idemia, whether statins could protect endothelium by
reducing ADMA concentration is unclear yet, and
whether this effect is associated with the dose of statins
usage is also needed further investigation. Taken to-
gether, in order to address the above questions, dyslip-
idemia animal models were produced and then were
treated with different doses of atorvastatin. We consid-
ered that the results from our present study could pro-
vide evidence regarding the potential therapeutic target
of ADMA as a function of prevention and treatment of
ASCVD in the future.
Methods
Animal model production
Sixty healthy male Sprague–Dawley rats weighing 200-
220 g were obtained from the Experimental Animal
Center of Sun Yat-sen University, Guangzhou, China.
The study was approved by the Ethic Committee of Sun
Yat-sen University. All animals received humane care in
compliance with the Guide for the Care and Use of
Laboratory Animals of the Institute of Laboratory Animal
Resources, National Research Council.
After 1 week of accommodation, dyslipidemia animal
model was produced in accordance to the previous
described protocol [14]. Briefly, 15 rats were randomly
selected and were used as the sham group, in which rats
were given diet as usual, and the other 45 rats, evenly
and randomly divided into 3 groups (n = 15), were used
to produce dyslipidemia model as given with high-fat and
high-cholesterol diet consisting of cholesterol (4.0%),
cholic acid (0.4%), propylthiouracilum (0.3%) and lard
(10.0%) for totally 8 weeks.
Protocol of medical treatment
At 8 weeks of dyslipidemia model production, 5 rats
from each group were randomly selected and sacrificed
for evaluating the parameters of interest. The rest rats
were given different medical treatments for totally
4 weeks. Briefly, rats with dyslipidemia were randomly
assigned into the control group (given 3 ml of saline
daily orally, n = 10), the low-dose atorvastatin group
(5 mg/kg body weight/day of atorvastatin, prescribedorally, n = 10) and the high-dose atorvastatin group
(20 mg/kg body weight/day of atorvastatin prescribed
orally, n = 10). Rats in the sham group (n = 10) were
orally given 3 ml of saline daily.
Parameters of interest assessment
At baseline, 8 weeks after dyslipidemia model produc-
tion, and 4 weeks after medical treatment, fasting venous
blood in each group were drawn for parameters of
interest assessment. Plasma levels of triglyceride (TG),
total cholesterol (TC), low density lipoprotein-cholesterol
(LDL-C), high density lipoprotein-cholesterol (HDL-C),
and fasting blood glucose (FBG) were detected by Auto-
matic Biochemistry Analyzer (Beckman coulter UniCel
DxC 800 Synchron). Plasma levels of ADMA (enzyme-
linking immune-absorbent assay kit, Wuhan Huamei Bio-
engineering Company, CSB-E13039r), malondialdehyde
(MDA assay Kit, Nanjin Jianchen Bioengineering Institute,
A003-2), C-reactive protein (CRP assay Kit, Nanjin Jian-
chen Bioengineering Institute, H151) and NO production
(Total Nitric Oxide Kit, Beyotime, Haimen, China, S0023)
were evaluated too. Briefly, the plasma level of ADMA
was detected by enzyme-linking immune-absorbent assay
in accordance to the manufacture’s instruction, and the
detected wavelength is 450 nm. The intra-assay and
inter-assay of coefficient variation were 9% and 11% re-
spectively. At 8 weeks of dyslipidemia model production
(5 rats from each group were randomly selected) and
4 weeks of medical treatment (the rest 10 rats in each
group), after venous blood was drawn, the hearts of rats
in each group were harvested for the evaluation of
ADMA concentration in cardiac tissues (enzyme-link-
ing immune-absorbent assay kit, Wuhan Huamei
Bioengineering Company, CSB-E13039r). Cardiac tis-
sues were homogenized and lysed with 500 μL of lysis
buffer (50 mM Tris–HCl, pH 7.5; 5 mM EDTA;
250 mM NaCl; and 0.1% Triton X-100) containing
20 μL (10 mg/ml) of protease inhibitors PMSF. Con-
centration of protein was measured by Bicinchoninic
acid (BCA) method. With respect to the safety of sta-
tins usage, liver enzymes (alanine aminotransferase,
ALT and aspartate aminotransferase, AST) and creatin-
ine kinase (CK) were also detected after 4 weeks of
atorvastatin therapy.
Statistical analyses
Continuous variable was presented as mean ± SD and
compared by the Student’s t-test when data was nor-
mally distributed, otherwise compared by Wilcoxon
rank-sum test. Categorical data was presented as per-
centage and compared by χ2 test. Statistical analyses
were performed by using SPSS software version 18.0
(SPSS, Inc., Chicago, Illinois). A value of p <0.05 was
considered significant.
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Baseline characteristics of rats in each group
In order to evaluate the changes of parameters of inter-
est pre- and post-medical treatment, baseline character-
istics of rats in each group were evaluated. As shown in
Table 1, plasma levels of lipid profiles and FBG were
comparable between groups at baseline. In addition,
plasma levels of ADMA, MDA and CRP, and NO pro-
duction were also detected and all the parameters were
comparable between groups.
Changes of parameters of interest pre- and post-medical
treatment
Parameters of interests before and after medical treat-
ment were evaluated and compared between groups. As
presented in Table 2, body weight and plasma levels of
lipid profiles were all significantly increased in the dyslip-
idemia groups as compared to the sham group, suggesting
that dyslipidemia model was successfully established. Of
note, FBG level was also concomitantly increased, indi-
cating that in the early stage of dyslipidemia, glucose
homeostasis was already impaired. Moreover, parameters
of inflammation, oxidation, and endothelial function were
also profoundly deteriorated in the dyslipidemia groups.
As shown in Table 2, plasma levels of CRP, MDA and
ADMA were significantly increased while NO production
was profoundly decreased in the dyslipidemia group when
compared to the sham group (p < 0.05). Nonetheless, im-
provements were observed after 4 weeks of medical treat-
ment. Notably, plasma levels of TG, TC and LDL-C were
significantly reduced in the high-dose atorvastatin group
as compared to the control group, and FBG level was also
slightly reduced. Moreover, plasma levels of CRP, MDA
and ADMA were significantly decreased, and NO produc-
tion was profoundly increased in the high-dose atorva-
statin group (p < 0.05). Briefly, improvements were also
observed in the low-dose atorvastatin group. However, no
statistical difference was observed when compared to the
control group. After 4 weeks of atorvastatin therapy, noTable 1 Baseline characteristics of rats
Variables Sham (n = 15) Control (n = 1
Body weight (g) 215.51 ± 2.70 213.24 ± 3.62
TG (mmol/L) 1.03 ± 0.06 1.06 ± 0.08
TC (mmol/L) 3.45 ± 0.11 3.52 ± 0.14
LDL-C (mmol/L) 2.05 ± 0.10 2. 08 ± 0.12
HDL-C (mmol/L) 0.93 ± 0.04 0.91 ± 0.04
FBG (mmol/L) 4.06 ± 0.05 4.10 ± 0.08
NO (umol/L) 11.73 ± 1.05 12.02 ± 1.14
CRP (mg/L) 2.16 ± 0.32 2.28 ± 0.33
MDA (nmol/L) 0.87 ± 0.04 0.90 ± 0.06
ADMA (ng/mL) 42.52 ± 6.40 44.75 ± 5.33significant differences of ALT, AST and CK levels between
groups were observed, suggesting that a short-term of
high-dose atorvastatin was safe.
Changes of ADMA concentration in cardiac tissues
pre- and post-medical treatment
At 8 weeks of model production and at 4 weeks of med-
ical treatment, after venous blood sample were drawn,
cardiac tissues were harvested and used for ADMA con-
centration evaluation. As presented in Table 3, at 8 weeks
of dyslipidemia model establishment, ADMA concentra-
tions in cardiac tissues were promoted as compared to
the sham group, nevertheless, after 4 weeks of atorva-
statin treatment, when compared to the control group,
ADMA concentration was significantly reduced in the
high-dose atorvastatin group (p < 0.05) but marginally
decreased in low-dose atorvastatin group (p = 0.078).
Discussion
Endothelial dysfunction induced by dyslipidemia is im-
plicated in the development and progression of athero-
sclerosis. Statins, a potent lipid-modified agent, has
potent effects on protecting endothelium through mul-
tiple mechanisms. Nonetheless, in the early stage of dys-
lipidemia, whether statins could reduce ADMA and
thereby improve endothelial function has not been fully
investigated yet. Moreover, whether this effect is associ-
ated with the dose of statins is also uncovered. Our
present study showed that in rats changing from healthy
to morbidity, high-dose of atorvastatin therapy con-
ferred profound protection on endothelium as reflecting
by increased NO production and reduced ADMA con-
centration in both plasma and cardiac tissues. Notably,
endothelium-protection with low-dose of atorvastatin
therapy did not achieve statistical significance when
compared to the control group, suggesting that in the
early stage of dyslipidemia, initiating high-dose of
statins therapy might promptly prevent endothelial
deterioration.5) Low-dose (n = 15) High-dose (n = 15)
216.45 ± 2.82 215.26 ± 3.33
1.03 ± 0.05 1.04 ± 0.07
3.36 ± 0.15 3.44 ± 0.13
2.06 ± 0.14 2.09 ± 0.12
0.90 ± 0.05 0.93 ± 0.03
4.08 ± 0.05 4.10 ± 0.08
11.81 ± 1.09 10.98 ± 1.04
2.17 ± 0.22 2.32 ± 0.35
0.89 ± 0.03 0.93 ± 0.05
43.90 ± 6.05 44.15 ± 5.20
Table 2 Changes of parameters of interest pre- and post-medical treatment
Variables Sham Control Low-dose High-dose
Pre-medical treatment (8 weeks of model production, n = 5 each group)
Body weight (g) 254.8 ± 6.6* 286.6 ± 7.0 290.3 ± 8.7 288.5 ± 10.4
TG (mmol/L) 1.15 ± 0.17* 1.79 ± 0.33 1.78 ± 0.32 1.76 ± 0.43
TC (mmol/L) 3.96 ± 0.26* 4.97 ± 0.34 4.96 ± 0.37 4.95 ± 0.45
LDL-C (mmol/L) 2.12 ± 0.24* 2.85 ± 0.31 2.91 ± 0.57 2.89 ± 0.44
HDL-C (mmol/L) 1.07 ± 0.12 1.11 ± 0.04 1.12 ± 0.04 1.10 ± 0.05
FBG (mmol/L) 4.12 ± 0.08* 4.49 ± 0.11 4.51 ± 0.12 4.50 ± 0.08
NO (umol/L) 12.67 ± 1.37* 9.65 ± 1.05 9.26 ± 1.08 9.44 ± 1.02
CRP (mg/L) 2.15 ± 0.42* 6.37 ± 0.55 6.52 ± 0.73 6.46 ± 0.52
MDA (nmol/L) 0.90 ± 0.06* 2.46 ± 0.18 2.57 ± 0.12 2.52 ± 0.19
ADMA (ng/mL) 43.37 ± 6.65* 60.68 ± 10.17 62.22 ± 8.17 62.30 ± 8.22
Post-medical treatment (4 weeks of medical treatment, n = 10 each group)
Body weight (g) 277.3 ± 8.2* 301.2 ± 7.4 299.6 ± 10.3 300.6 ± 10.5
TG (mmol/L) 1.17 ± 0.22* 1.83 ± 0.42 1.67 ± 0.37 1.50 ± 0.29#
TC (mmol/L) 3.98 ± 0.33* 5.00 ± 0.62 4.81 ± 0.56 4.56 ± 0.36#
LDL-C (mmol/L) 2.13 ± 0.23* 2.87 ± 0.36 2.64 ± 0.52 2.43 ± 0.35#
HDL-C (mmol/L) 1.07 ± 0.14 1.10 ± 0.05 1.12 ± 0.03 1.10 ± 0.03
FBG (mmol/L) 4.14 ± 0.07* 4.56 ± 0.13 4.46 ± 0.15 4.41 ± 0.13
NO (umol/L) 12.88 ± 1.56* 9.03 ± 0.68 10.07 ± 0.64 10.85 ± 0.57#
CRP (mg/L) 2.13 ± 0.39* 6.43 ± 0.42 5.87 ± 0.16 5.35 ± 0.66#
MDA (nmol/L) 0.93 ± 0.07* 2.52 ± 0.15 2.29 ± 0.09 2.05 ± 0.07#
ADMA (ng/mL) 44.64 ± 7.08* 62.33 ± 10.08 58.75 ± 8.07 54.46 ± 9.15#
ALT (U/L) 21.43 ± 3.24 26.55 ± 5.21 24.47 ± 6.08 22.39 ± 3.76
AST (U/L) 24.36 ± 6.77 22.55 ± 4.09 21.56 ± 3.35 23.30 ± 6.12
CK (U/L) 18.24 ± 2.23 21.30 ± 2.08 20.07 ± 3.35 20.35 ± 2.56
Denote: *P < 0.05 versus other groups, #P < 0.05 versus control group.
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stone therapy for the primary and secondary prevention of
ASCVD. Other than potent lipid-lowering effect, statins
could exert other pleiotropic effects on cardiovascular
systems [15,16]. For example, statins could ameliorate
inflammation and oxidation in rats after acute myocar-
dial infarction as reported by previous basic research
[17]. Statins could enhance NO production by stabilizing
the mRNA of eNOS [6,18]. Moreover, statins is capable
of promoting endothelial progenitor cells migration and
facilitating angiogenesis [19,20]. Consistent with previous
reports [19,20], results from our present study revealedTable 3 Changes of ADMA concentration in cardiac tissues
Variables Sham C
Pre-medical treatment (8 weeks of model production, n = 5 each group
ADMA (μmol/mg protein) 35.15 ± 6.03* 4
Post-medical treatment (4 weeks of medical treatment, n = 10 each gro
ADMA (μmol/mg protein) 36.08 ± 7.43* 5
Denote: *P < 0.05 versus other groups, #P < 0.05 versus control group.that atorvastatin therapy, with either low-dose or high-
dose, could reduce plasma levels of CRP and MDA. NO
production was also concomitantly enhanced with atorva-
statin treatment. Nonetheless, with respect to the statis-
tical significance, only high-dose of atorvastatin therapy
achieved significant improvement on endothelial function
as compared to the control group.
Knowingly, ADMA is a specific inhibitor of eNOS and
many previous research have revealed that increased
ADMA level was associated with adverse cardiovascular
outcomes [21-23]. The underlying mechanism might be
partially attributed to the adverse effects ADMA playedontrol Low-dose High-dose
)
8.53 ± 8.08 50.44 ± 10.52 49.67 ± 7.33
up)
1.51 ± 8.26 47.26 ± 8.27 41.50 ± 7.08#
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protecting endothelium, statins exerts its pleiotropic
effects on cardiovascular system. Nevertheless, whether
these benefits are associated with ADMA reduction is
not fully investigated yet. Results from our present study
revealed that atorvastatin therapy could reduce both the
plasma level of ADMA as well as the ADMA concentra-
tion in cardiac tissues in rats with dyslipidemia after
4 weeks’ therapy. These benefits were enhanced with
high-dose of atorvastatin regimen, while no statistical
difference was observed between the low-dose of regi-
men and the control group, which we considered might
be due to the short-term of atorvastatin therapy in the
low-dose group as previous many studies have shown
that the efficacy of statins therapy was associated with
the duration of its usage [19,20]. The underlying mech-
anism associated with atorvastatin therapy on ADMA
reduction was not investigated in our present study.
However, to the best of our knowledge, we considered
some mechanisms might be used to explain our findings.
In the first place, it was possible that through modifying
dyslipidemia, atorvastatin decreases plasma ADMA level.
Data from our present study could provide evidence
supporting this notion. As shown in Tables 1 and 2,
when compared to baseline, plasma ADMA level was
increased in accompanying with lipid disorders after
8 weeks’ high-fat and high-cholesterol diet treatment. In
contrast, plasma ADMA level was concomitantly re-
duced when lipid disorders were improved by both low-
dose and high-dose of statins therapy. Although there
appeared to be a positive relationship between lipid
disorders and ADMA change in our present research,
we still could not definitely conclude that dyslipidemia
was the unique and definitive cause of ADMA elevation.
Secondly, since endothelium-protection by statins therapy
is evident, it was therefore possible that atorvastatin could
antagonize ADMA by directly up-regulating eNOS ex-
pression and promoting NO production. In the future,
using eNOS knock-out animal model might be helpful to
find out whether ADMA reduction by statins therapy was
dependent on eNOS/NO signaling pathway. Thirdly, since
statins has pleiotropic effects on different signaling
pathway, therefore, it was possible that atorvastatin
might regulate ADMA metabolism through promoting
the activity of dimethylarginine dimethylaminohydro-
lase (DDAH) or regulating ADMA synthesis through
inhibiting protein arginine N-methyltransferase (PRMT).
In the future, it is warranted to investigate whether sta-
tins has effects on DDAH or PRMT. Last but not the
least, the change of ADMA during the initiation and
progression of atherosclerosis might be multi-factorial
and atorvastatin might directly reduce ADMA level
through modulating the gene expression or mRNA
transcription.Conclusion
In summary, results from our present study show that in
rats with dyslipidemia, atorvastatin therapy could reduce
plasma level of ADMA and ADMA concentration in
cardiac tissues, and these effects are more prominent by
high-dose of atorvastatin therapy, suggesting that high-
dose of statins therapy may confer rapid protection on
endothelium, and future study is warranted to investi-
gate whether this early benefit could ultimately turn into
long-term clinical benefit.
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